Status:
COMPLETED
RETRIEVE-AMI Study
Lead Sponsor:
Oxford University Hospitals NHS Trust
Collaborating Sponsors:
Medtronic
Terumo Corporation
Conditions:
Myocardial Infarction
Thrombus
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Heart attacks are caused by the sudden formation of a clot inside a diseased coronary artery which reduces blood flow beyond the blockage site. During conventional treatment of the blockage with what ...
Eligibility Criteria
Inclusion
- Primary PCI patient with ST elevation myocardial infarction (STEMI)
- TIMI 0/1 flow at presentation
- Angiographic thrombus score ≥ 4
- Vessel diameter at site of occlusion ≥ 3.0 mm (measured by quantitative coronary angiography)
Exclusion
- Female participant who is pregnant or lactating
- Participant with known hypersensitivity to nickel-titanium
- Unconscious at presentation
- Late presenter (pain to wire time \> 12 h)
- Class Killip III/IV and/or profound bradycardia (Heart rate \< 40 bpm)
- Known history of kidney failure
- Ostial occlusion
- Highly tortuous vessel
- Highly calcified vessel
- Suspected (angiographically) spontaneous coronary artery dissection
- Stent thrombosis
- Previous stent implanted proximal to the occlusion site
- Previous coronary artery bypass graft surgery (CABG)
- Previous STEMI/Transient Ischemic Attack/Stroke
- Known anaemia (Hemoglobin \<9)
Key Trial Info
Start Date :
May 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2025
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT05307965
Start Date
May 6 2022
End Date
May 28 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford Heart Centre
Oxford, United Kingdom, OX3 9DU